PharmaKure Announces Successful Scientific Advice Meeting with the MHRA.
Manchester, United Kingdom 6th February 2023
PharmaKure Sponsors the Multiple Systems Atrophy (MSA) Research Symposium at UCL on the 20th January, 2023.
Manchester, United Kingdom 20th January 2023
PharmaKure Announces Move of Headquarters to Circular 1 Health in Didsbury Manchester
Manchester, United Kingdom 17th October 2022
PharmaKure has launched a study to identify blood-based biomarkers in patients with Alzheimer’s Disease.
Manchester, United Kingdom 4th October 2022
PharmaKure Announces a Blood Biomarker Study
1st July 2022. PharmaKure announce a ground breaking study of a blood biomarker trial using their proprietary ALZmetrix® assay with Alzheimer's disease patients.
PharmaKure completes the acquisition of the CynapseDx Business with Financing involving the UK Government Future Fund.
March 26th 2021. PharmaKure is delighted to announce the completion of the acquisition of the CynapseDx assays for oligomeric proteins. This is the final step that secured invesment of £4 million from a private investor and the UK Future Fund to finance clinical trials on their leading drug candidate PK051 for Alzheimer's disease.
PharmaKure signs letter of intent with CynapseDx
PharmaKure Limited and CynapseDx Limited have signed a letter of intent for a commercial relationship between the two companies which could result in a collaboration or acquisition to secure funding.